Goldman Sachs maintains Buy rating on Medline with a 12-month target price of $50

Overview

This report summarizes key takeaways on Medline Inc. following Goldman Sachs' 47th Annual Global Healthcare Conference. Management was represented by CEO Jim Boyle and CFO Mike Drazin. The core message is that the company remains confident in its 2026 growth outlook and believes both Supply Chain Solutions and Medline Brands have multiple growth levers. The report also notes that 2026 still has characteristics of a transition year at the P&L level, mainly due to incremental tariff pressure, inflation, and onboarding investments for new customers, but the company's long-term goal is for adjusted EBITDA dollar growth to match or exceed revenue growth.

Core views

Goldman Sachs' core view is positive: first, healthcare utilization has not yet shown clear near-term weakening, although the company has reflected potential slowing in its guidance; second, there is still significant room for expansion in the private-label portfolio, especially in Lab & Diagnostics; third, management described the quality control system as robust, with recent recalls having limited financial impact; fourth, input costs and tariffs have an offsetting relationship in the second half, and management prefers to maintain pricing discipline to continue gaining share; fifth, after deleveraging, M&A could become a further upside driver.

Analysis framework

Based on management's conference remarks and Q&A, the report evaluates the 2026 guidance, healthcare demand, quality control, Medline Brands penetration, costs and tariffs, margin leverage, and capital allocation item by item, and combines these with the target price valuation framework to reach its investment conclusion.

Methodology notes

• Conference notesManagement key-point tracking

  Validate assumptions on growth, cost, quality, and capital allocation through conference remarks

  The report mainly distills statements from the CEO and CFO at the global healthcare conference to update its judgment on Medline's 2026 outlook and medium- to long-term margin expansion path.

• Valuation methodEV/EBITDA multiple valuation

  The 12-month target price is based on 19.5x GSe Q5-Q8 adjusted EBITDA estimates

  Goldman Sachs' $50 target price uses 19.5x GSe Q5-Q8 adjusted EBITDA estimates, and the report does not provide a more detailed sum-of-the-parts valuation table.

• Goldman Sachs appendix frameworkGS Factor Profile

  Compare stock characteristics across four dimensions: Growth, Financial Returns, Multiple, and Integrated

  The appendix explains that GS Factor Profile uses normalized rankings and percentiles to measure growth, financial returns, valuation multiples, and integrated characteristics, providing investment context relative to the market and peers.

• Goldman Sachs appendix frameworkM&A Rank

  Use a 1 to 3 scale to assess the probability of a company becoming an acquisition target

  The appendix explains Goldman Sachs' M&A Rank framework, where 1 represents high probability, 2 medium probability, and 3 low probability; the main text notes that M&A is a potential upside driver for Medline, but does not disclose a specific M&A Rank.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Medline Inc. (MDLN.O)

  Core research target; Goldman Sachs covers the stock with a Buy rating.

  Strengths

  Management reaffirmed the 2026 growth outlook and believes the company continues to gain share in key categories; Medline Brands expansion, operating leverage, and M&A provide long-term upside potential.

  Weaknesses

  2026 P&L is still in a transition period, with onboarding investments for new customers, inflation, fuel and material costs, and one-time conversion rebates potentially weighing on near-term margins.

  Comparison

  The company emphasized it will not immediately raise prices due to short-term cost pressure, a strategy that has historically helped it gain share relative to competitors; its private-label offerings still have room for further substitution versus third-party distributed products.

  Risks

  Key risks include slowing healthcare utilization, adverse changes in tariffs and trade policy, slower-than-expected conversion of new contract wins into revenue, rising costs, intensified competition, and any expansion of quality control or recall issues.

Key data

• Report date2026-06-09The report time is 9 June 2026 10:34AM PDT.
• RatingBuyThe valuation section explicitly states, “We are Buy rated”.
• 12-month target price$50The target price is based on 19.5x GSe Q5-Q8 adjusted EBITDA estimates.
• Reference current price$33.80The company disclosure page lists Medline Inc.'s price as $33.80.
• Potential upsideabout 47.9%Calculated based on the $50 target price and the $33.80 reference price.
• Medline Brand substitution ratiocurrently about 60%, five-year target 75%Refers to the proportion of third-party products flowing through the distribution business that can be substituted.
• Lab & Diagnostics opportunityMedline about $1bn versus a market of about $25bnManagement said this is one of the most important opportunities within Medline Brands.
• Quality control investmentmore than $200mn, with another $20mn in 2026Management said this investment grows with revenue and capacity expansion and is not solely aimed at recent events.
• Multi-source manufacturing rationearly 90%Management said nearly 90% of manufactured products are multi-sourced, one reason the recall's financial impact is not material.
• Private fleet size2,000 owned trucksRising fuel costs could therefore pressure 2H P&L.

Impact & implications

The implication for the investment view is that Medline's medium- to long-term growth story still mainly comes from market share gains, private-label penetration, scale leverage, and potential M&A; in the short term, it remains necessary to verify whether the company can maintain revenue growth and margin recovery in an environment of potentially slowing healthcare utilization, rising costs, and tariff uncertainty. The Buy rating and $50 target price indicate Goldman Sachs believes the current share price still has meaningful upside.

Risks

• Healthcare utilization may slow due to legislation reducing insurance coverage.
• Tariff policy or other international trade restrictions may change unfavorably.
• New contract wins may convert into revenue more slowly than expected.
• The company may be unable to continue providing products at a cost meaningfully discounted relative to competitors.
• Recent strategic activity or industry growth may bring more focused direct competition.
• Rising input costs such as fuel, resin, and plastics may drag on 2H P&L.
• Although management said the recent recalls are not financially material, quality control and recall scope still require ongoing monitoring.

What to watch

• Whether healthcare utilization slows later in the year, and whether deferred care converts into higher-acuity interventions and higher supply costs.
• Whether tariffs revert after August to pre-SCOTUS ruling levels as guided by the company and offset second-half input cost pressure.
• Whether the Medline Brand substitution ratio can advance from about 60% toward the five-year target of 75%.
• Whether the Lab & Diagnostics business can expand share within an addressable market of about $25bn.
• When the impact of onboarding investments and conversion rebates for new Prime Vendor customers on near-term margins will ease.
• Whether deleveraging, free cash flow generation, and the pace of M&A become new upside catalysts.